ZA200401000B - Adenosine A3 receptor agonists. - Google Patents

Adenosine A3 receptor agonists. Download PDF

Info

Publication number
ZA200401000B
ZA200401000B ZA200401000A ZA200401000A ZA200401000B ZA 200401000 B ZA200401000 B ZA 200401000B ZA 200401000 A ZA200401000 A ZA 200401000A ZA 200401000 A ZA200401000 A ZA 200401000A ZA 200401000 B ZA200401000 B ZA 200401000B
Authority
ZA
South Africa
Prior art keywords
optionally substituted
compound
alkyl
heteroaryl
aryl
Prior art date
Application number
ZA200401000A
Other languages
English (en)
Inventor
Elfatih Elzein
Venkata Palle
Vaibhav Varkhedkar
Jeff Zablocki
Original Assignee
Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutics Inc filed Critical Therapeutics Inc
Publication of ZA200401000B publication Critical patent/ZA200401000B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA200401000A 2001-08-08 2004-02-06 Adenosine A3 receptor agonists. ZA200401000B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31106901P 2001-08-08 2001-08-08

Publications (1)

Publication Number Publication Date
ZA200401000B true ZA200401000B (en) 2004-10-18

Family

ID=23205248

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200401000A ZA200401000B (en) 2001-08-08 2004-02-06 Adenosine A3 receptor agonists.

Country Status (20)

Country Link
US (1) US20030078232A1 (cg-RX-API-DMAC7.html)
EP (1) EP1414837B1 (cg-RX-API-DMAC7.html)
JP (1) JP4357960B2 (cg-RX-API-DMAC7.html)
KR (1) KR100923888B1 (cg-RX-API-DMAC7.html)
CN (1) CN1244589C (cg-RX-API-DMAC7.html)
AT (1) ATE307136T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002327426C1 (cg-RX-API-DMAC7.html)
CA (1) CA2456744A1 (cg-RX-API-DMAC7.html)
DE (1) DE60206775T2 (cg-RX-API-DMAC7.html)
DK (1) DK1414837T3 (cg-RX-API-DMAC7.html)
ES (1) ES2247371T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0401437A3 (cg-RX-API-DMAC7.html)
IL (2) IL160231A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04001185A (cg-RX-API-DMAC7.html)
NO (1) NO327997B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ530976A (cg-RX-API-DMAC7.html)
PL (1) PL368205A1 (cg-RX-API-DMAC7.html)
RU (1) RU2298557C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003014137A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200401000B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US6914053B2 (en) * 2002-09-09 2005-07-05 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
NZ585697A (en) 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
CN101083998A (zh) * 2004-11-22 2007-12-05 王者制药研究发展有限公司 用腺苷a3受体激动剂强化治疗hif-1介导的病症
EP1845973B1 (en) 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US7514417B2 (en) 2005-05-19 2009-04-07 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7488720B2 (en) 2005-10-13 2009-02-10 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
JP5703432B2 (ja) * 2007-03-28 2015-04-22 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
EP2142546B1 (en) 2007-03-28 2017-06-07 Saniona A/S Purinyl derivatives and their use as potassium channel modulators
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
JP2011500716A (ja) * 2007-10-16 2011-01-06 ギリアード・パロ・アルト・インコーポレイテッド A3アデノシン受容体アンタゴニスト
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
EP2885290B1 (en) 2012-06-26 2017-10-18 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
CN120647702A (zh) * 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
US20220332750A1 (en) * 2019-06-21 2022-10-20 Academy Of Military Medical Sciences Adenosine compound, its pharmaceutically acceptable salt or its stereoisomer and use thereof
JP2024502068A (ja) * 2020-12-29 2024-01-17 チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド A3アデノシン受容体アゴニスト及びその調製方法と用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists

Also Published As

Publication number Publication date
EP1414837A1 (en) 2004-05-06
AU2002327426C1 (en) 2008-03-06
KR100923888B1 (ko) 2009-10-28
HUP0401437A2 (hu) 2004-11-29
JP4357960B2 (ja) 2009-11-04
AU2002327426A2 (en) 2003-02-24
PL368205A1 (en) 2005-03-21
DE60206775D1 (de) 2006-03-02
RU2004106635A (ru) 2005-07-27
EP1414837B1 (en) 2005-10-19
RU2298557C2 (ru) 2007-05-10
NO20040969L (no) 2004-04-19
US20030078232A1 (en) 2003-04-24
IL160231A0 (en) 2004-07-25
IL160231A (en) 2010-11-30
CN1244589C (zh) 2006-03-08
NO327997B1 (no) 2009-11-09
DE60206775T2 (de) 2006-07-20
CN1538972A (zh) 2004-10-20
KR20040023733A (ko) 2004-03-18
HUP0401437A3 (en) 2007-05-29
WO2003014137A1 (en) 2003-02-20
NZ530976A (en) 2005-07-29
ES2247371T3 (es) 2006-03-01
DK1414837T3 (da) 2005-11-07
CA2456744A1 (en) 2003-02-20
AU2002327426B2 (en) 2007-06-14
ATE307136T1 (de) 2005-11-15
MXPA04001185A (es) 2005-06-17
JP2005501842A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
EP1414837B1 (en) Adenosine a3 receptor agonists
AU2002327426A1 (en) Adenosine A3 receptor agonists
CA2451244C (en) Purine derivatives as a2b adenosine receptor antagonists
CA2702644A1 (en) A3 adenosine receptor antagonists
US7262176B2 (en) Adenosine A3 receptor agonists
WO2003006465A1 (en) Partial and full agonist of a adenosine receptors
AU2004209986B2 (en) Partial and full agonists of A1 adenosine receptors
EP1646390B1 (en) A1 adenosine receptor antagonists
EP1537135B1 (en) Adenosine a3 receptor agonists
EP1456209B1 (en) A2a adenosine receptor antagonists
EP1943251B1 (en) A1 adenosine receptor agonists
HK1093422B (en) A1 adenosine receptor antagonists